West Virginia House Advances Medical Cannabis Revenue Allocation Bill

The West Virginia House of Delegates passed legislation Wednesday directing how the state will allocate revenue from its fledgling medical marijuana program, with an unexpected amendment proposing psychedelic research funding drawing both support and skepticism.

The bill cleared the chamber after debate over whether cannabis tax dollars should fund research into psilocybin and other psychedelics. "I don't want to waste the money on something not dedicated to cannabis," said one lawmaker opposing the psychedelic research provision, according to Mountain State Spotlight.

West Virginia launched medical cannabis sales in late 2023, making it one of the last states in the region to implement a working program. The revenue allocation bill comes as the state begins collecting its first substantial tax receipts from dispensary operations.

The Revenue Plan

The legislation establishes specific funding channels for medical marijuana tax revenue, though exact allocation percentages weren't detailed in initial reporting. The bill's primary focus targets cannabis-related initiatives including program administration, medical research, and regulatory oversight.

But the psychedelic research amendment has emerged as the measure's most contentious element. Some delegates argued that expanding into psilocybin and MDMA research represents forward-thinking drug policy, particularly as FDA approval processes advance for psychedelic-assisted therapies.

Others maintain the state should concentrate resources exclusively on understanding cannabis—the substance voters actually approved. West Virginia's medical marijuana program currently serves patients with qualifying conditions including chronic pain, PTSD, and cancer.

What Happens Next

The bill now moves to the West Virginia Senate, where it faces an uncertain path. Senate leadership hasn't indicated whether they'll embrace or strip out the psychedelic research language.

Timing matters here. The state's fiscal year ends June 30, and lawmakers want revenue allocation mechanisms in place before substantial tax receipts accumulate. West Virginia's medical cannabis program generated modest early sales, but industry observers expect revenue to climb as more dispensaries open and patient counts grow.

The debate mirrors broader national conversations about drug policy evolution. While marijuana legalization advances state by state, psychedelic reform has gained momentum separately—Oregon and Colorado have passed decriminalization measures, and cities from Denver to Detroit have deprioritized enforcement.

Yet combining the two in revenue legislation remains novel. Most states with established cannabis programs dedicate tax dollars to substance abuse treatment, education, or general funds. Few have explicitly linked marijuana revenue to psychedelic research funding.

West Virginia's approach, if it survives the Senate, could set precedent for other states looking to fund emerging drug research without tapping general appropriations. Or it could serve as a cautionary tale about mission creep in cannabis policy.

The House vote Wednesday represents just one step in the legislative process. Amendments, committee reviews, and final passage votes all remain before any revenue allocation becomes law.

This article is based on original reporting by www.marijuanamoment.net.